ArticleFrontiers in cardiovascular medicine2025
Inflammatory biomarkers as predictors of prognosis in patients after transcatheter aortic valve implantation.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preprocedural Biomarkers of Inflammation and Fibrosis and Echocardiographic Markers of Myocardial Remodeling in New-Onset Conduction Disorders After Transcatheter Aortic Valve Implantation.Medicina (Kaunas, Lithuania) · 2026Observational
- De Ritis (AST/ALT) ratio as a predictor of early adverse outcomes following transcatheter aortic valve replacement.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The expanding role of transcatheter aortic valve implantation (TAVI) highlights the need to identify factors influencing long-term outcomes. Systemic inflammatory response syndrome (SIRS) is a frequent post-procedural event that may adversely affect prognosis. Measurement of inflammatory biomarkers may improve the understanding of underlying mechanisms and refine patient risk stratification. Methods: This single-center, prospective cohort study, enrolled 62 consecutive patients undergoing TAVI, who were followed for up to 5 years. Blood samples were collected before TAVI, at 24 h and 3-6 months post-procedure. Changes in biomarker levels, predictors of SIRS, and inflammatory predictors of long-term outcomes were analyzed. Results: SIRS developed in 45% of patients. Significant temporal changes were observed in hs-CRP, TNF-α, sST2/IL-33, IL-10, and IL-2 levels, irrespective of baseline or procedural characteristics. The development of SIRS was associated with a higher risk of all-cause mortality or unplanned hospitalization at 5 years (HR 3.07, 95% CI 1.57-6.00; Conclusions: SIRS is a common post-TAVI phenomenon and may be linked to long-term outcomes. Elevated pre-procedural hs-CRP and IFN-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.